Liver segment 2+3 living donation in liver transplantation for colorectal liver metastases

Dueland, Svein; Line, Pål-Dag

doi:10.21037/hbsn.2019.11.15

Cited by 3 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eight trials for LT in CRLM are registered on clinicaltrials.gov at time of writing spanning six countries (Table 2). Three RCTs plus one study with a randomised element [19–22], three single group assignments [23–25] and two non‐randomised trials with parallel trials to be used as comparison groups [22, 26]. Interventions include living donor (LD) transplantation [23, 24], deceased donor (DD) transplantation [21, 22, 25, 26], extended criteria donor (ECD) transplantation [20] and liver transplantation with staged/delayed hepatectomy [23, 25].…”

Section: Resultsmentioning

confidence: 99%

“…Three RCTs plus one study with a randomised element [19–22], three single group assignments [23–25] and two non‐randomised trials with parallel trials to be used as comparison groups [22, 26]. Interventions include living donor (LD) transplantation [23, 24], deceased donor (DD) transplantation [21, 22, 25, 26], extended criteria donor (ECD) transplantation [20] and liver transplantation with staged/delayed hepatectomy [23, 25]. The RCT comparison arms consist of standard chemotherapy regimens or “best alternate care”.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Liver Transplantation for Non‐Resectable Liver Metastases from Colorectal Cancer: A Systematic Review and Meta‐Analysis

et al. 2021

View full text Add to dashboard Cite

Backgrounds Colorectal liver metastases were historically considered a contraindication to liver transplantation, but dismal outcomes for those with metastatic colorectal cancer and advancements in liver transplantation (LT) have led to a renewed interest in the topic. We aim to compare the current evidence for liver transplantation for non-resectable colorectal liver metastases (NRCLM) with the current standard treatment of palliative chemotherapy. Methods A systematic review and meta-analysis of proportions was conducted following screening of MEDLINE, EMBASE, SCOPUS and CENTRAL for studies reporting liver transplantation for colorectal liver metastases. Post-operative outcomes measured included one-, three- and five-year survival, overall survival, disease-free survival and complication rate. Results Three non-randomised studies met the inclusion criteria, reporting a total of 48 patients receiving LT for NRCLM. Survival at one-, three- and five-years was 83.3–100%, 58.3–80% and 50–80%, respectively, with no significant difference detected (p = 0.22, p = 0.48, p = 0.26). Disease-free survival was 35–56% with the most common site of recurrence being lung. Thirteen out of fourteen deaths were due to disease recurrence. Conclusion Although current evidence suggests a survival benefit conferred by LT in NRCLM compared to palliative chemotherapy, the ethical implications of organ availability and allocation demand rigorous justification. Concomitant improvements in the management of patients following liver resection and of palliative chemotherapy regimens is paramount.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Liver Transplantation for Non‐Resectable Liver Metastases from Colorectal Cancer: A Systematic Review and Meta‐Analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In this setting, two important studies proposed alternative options to increase the donor pool. The RAPID concept ( 37 ) and the use of living donor (Toronto Protocol) have been recently proposed and are currently under investigation ( 38 ).…”

Section: Colon Rectal Liver Metastases As a New Indication To Lt: The Challenging Of The Prioritizationmentioning

confidence: 99%

Colon Rectal Liver Metastases: The Role of the Liver Transplantation in the Era of the Transplant Oncology and Precision Medicine

et al. 2021

View full text Add to dashboard Cite

The development of liver metastases in colon rectal cancer has a strong impact on the overall survival (OS) of the patient, with a 5-year survival rate of 5% with palliative treatment. Surgical resection combined with pharmacological treatment can achieve a 5-year OS rate of 31–58%. However, in only 20% of patients with colon rectal liver metastases (CRLMs), liver resection is feasible. In highly selected patients, recent trials and studies proved that liver transplantation (LT) for non-resectable CRLM is a surgical option with an excellent long-term OS. The paper aims to review the indications and outcome of LT for CRLMs, with a special focus on immunosuppressive therapy and the management of local and extrahepatic recurrence after LT.

show abstract

Minimizing the risk of small-for-size syndrome after liver surgery

Heaton

Papamichail

Pizanias

et al. 2022

Hepatobiliary & Pancreatic Diseases International

View full text Add to dashboard Cite

Liver segment 2+3 living donation in liver transplantation for colorectal liver metastases

Cited by 3 publications

References 9 publications

Liver Transplantation for Non‐Resectable Liver Metastases from Colorectal Cancer: A Systematic Review and Meta‐Analysis

Liver Transplantation for Non‐Resectable Liver Metastases from Colorectal Cancer: A Systematic Review and Meta‐Analysis

Colon Rectal Liver Metastases: The Role of the Liver Transplantation in the Era of the Transplant Oncology and Precision Medicine

Minimizing the risk of small-for-size syndrome after liver surgery

Contact Info

Product

Resources

About